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The role of PD-L1 as a prognostic and predictive biomarker is an area of great interest. However, there is a lack of consensus on
how to deliver PD-L1 as a clinical biomarker. At the heart of this conundrum is the subjective scoring of PD-L1 IHC in most studies
to date. Current standard scoring systems involve separation of epithelial and inflammatory cells and find clinical significance
in different percentages of expression, e.g., above or below 1%. Clearly, an objective, reproducible and accurate approach to PD-
L1 scoring would bring a degree of necessary consistency to this landscape. Using a systematic comparison of technologies and
the application of QuPath, a digital pathology platform, we show that high PD-L1 expression is associated with improved clinical
outcome in Triple Negative breast cancer in the context of standard of care (SoC) chemotherapy, consistent with previous findings.
In addition, we demonstrate for the first time that high PD-L1 expression is also associated with better outcome in ER- disease as a
whole including HER2+ breast cancer.We demonstrate the influence of antibody choice on quantification and clinical impact with
the Ventana antibody (SP142) providing the most robust assay in our hands. Through sampling different regions of the tumour, we
show that tumour rich regions display the greatest range of PD-L1 expression and this has the most clinical significance compared
to stroma and lymphoid rich areas. Furthermore,we observe that both inflammatory and epithelial PD-L1 expression are associated
with improved survival in the context of chemotherapy. Moreover, as seen with PD-L1 inhibitor studies, a low threshold of PD-L1
expression stratifies patient outcome.This emphasises the importance of using digital pathology and precise biomarker quantitation
to achieve accurate and reproducible scores that can discriminate low PD-L1 expression.
1. Introduction
DNA-based high-throughput mutational analysis [1, 2] and
high-throughput gene expression profiling [3] have demon-
strated that breast cancer is a heterogeneous disease and
treatment options must reflect this. Despite major break-
throughs such as the targeted therapies against the estrogen
receptor (ER) or oncogenic proteins such as HER2, 20% of
patients will relapse with secondary breast cancer, which is
currently incurable. This may be due to the underlying inter-
and intratumoural heterogeneity leading to intrinsic and/or
acquired resistance to therapy, or to basicmolecular pathways
(such as angiogenesis) not controlled by these therapies.
It has long been thought that the ultimate cure for cancer
would arise from harnessing the host immune system that,
through its adaptive nature, could eradicate cancer cells
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even as they evolve. Indeed, in breast cancer, the presence
of Tumour Infiltrating Lymphocytes (TILs) is a positive
prognostic factor [4, 5] and a number of immune based
gene expression signatures identify good outcome subgroups
especially within the poor outcome triple negative subgroup
[6–9]. Central to this is the theory of immunosurveillance,
dating from the 1950s [10] and the subsequent concept of
immunoediting, providing a major selective pressure for
cancer cells to acquireways of evading and/or neutralising the
immune cells [10].This is borne out in the twomain immune
phenotypes observed in a range of solid tumours [11], namely,
T-cell rich and T-cell poor (the latter associated with denser
stroma and alternative macrophage populations). The T-cell
rich tumours are associated with an inflamed microenviron-
ment and high expression of immune inhibitory pathways
that allow the tumour to evade destruction by these cells. One
such pathway is the PD1/PD-L1 immune checkpoint pathway.
Expression of PD-L1 is observed in multiple cancer subtypes
including breast, suggesting that cancer cells have hijacked
this mechanism in order to evade immune mediated destruc-
tion [12, 13]. This observation is the basis for drug targeting
by immune checkpoint inhibitors allowing reactivation of the
immune system [14]. Clinical trials in multiple cancer types
have shown some remarkably durable responses as reviewed
by [15].
Most predictors of drug response also have a pure
prognostic value. Indeed, PD-L1 expression has been studied
in multiple cancer types and correlated with various clinico-
pathological parameters [16–19]. In general, studies to date
have used different monoclonal antibodies for immunohisto-
chemistry (IHC) and different techniques beyond IHC [20–
24], with different scoring systems and in different clinical
trial materials (reviewed in [25–27]) providing inconsistent
findings. This is also the case in breast cancer. Whereas early
studies demonstrated that PD-L1 expression was associated
with other poor prognostic factors [28–30], later studies have
qualified this observation in triple negative (TNBC) and/or
basal-like breast cancer [20, 24, 31, 32]. Subject to the same
technical inconsistencies, PD-L1 itself has been shown to be
both a positive and negative prognostic factor, although most
studies indicate that high PD-L1 expression is associated with
better clinical outcome as well as increased TILs [21, 23, 24].
Furthermore, high PD-L1 expression has been reported to
be a predictive biomarker of neo-adjuvant chemotherapy
[20, 23, 33].
At the heart of this conundrum is the subjective scoring
of PD-L1 IHC. Current standard scoring systems for PD-L1
as a companion diagnostic involve separation of epithelial
and inflammatory cells and find clinical significance in
percentages of expression above or below 1% [34, 35]. Clearly,
an objective, reproducible and accurate approach to PD-L1
assessment would bring a degree of necessary consistency to
this landscape. Therefore, we present a systematic compari-
son of technologies and scoring systems and the application
of QuPath, a digital pathology platform [36], to the scoring
of PD-L1 in breast cancer, starting with TNBC as a paradigm,
and then extending its application to breast cancer as a whole.
We show how QuPath’s analytical tools (automated tumour
recognition, automated separation of epithelial and immune
compartments, and dynamic threshold identification) con-
firm many of the observations stated before and add further
insight to the value of PD-L1 expression in breast cancer
subgroups.
2. Materials and Methods
2.1. Study Design and Patient Selection. We conducted a
retrospective case-control study involving a cohort of TNBC
patients; ethical approval was obtained and tissue was
acquired through the Northern Ireland Biobank (NIB ref:
15-0168). The dataset was compiled for a cohort of 109
patients and included a range of clinical and pathological
parameters (Supp Table 1a). All of the resection samples
were processed and reported in the Belfast Health and Social
Care Trust. Surgical resection of tumour was performed
between 2000 and 2013 with a median follow-up of four
years. All breast cancer resection samples were placed into
10% buffered formalin for 48-72 hours to allow adequate
sample fixation. All samples were from Cellular Pathology
Laboratory, Belfast Health and Social Care Trust and were
fixed and processed to paraffin using UKAS accredited
standard protocols. Paraffin-embedded blocks were stored in
a cool, sunlight free environment. Original hormone receptor
and HER2 scores were available to define the TNBC cohort.
This was then confirmed following construction of the tissue
microarray (TMA). Patient exclusion criteria included male
sex and past history of cancer of any type. Additional cohorts
used in this study have been previously described in detail
[37] with a summary provided (Supp Table 1b).
2.2. TMA Construction. Original haematoxylin and eosin
(H&E)-stained sections of all of the blocks were reviewed
for tumour block selection. Following block selection, a
new H&E section was cut and the slide was annotated
for TMA construction. Where possible, from each selected
donor block, nine representative areas were annotated for
targeted coring – 3 tumour epithelial rich cores (T), 3 tumour
cores from lymphoid rich areas (TL), and 3 stromal rich
tumour cores (TS) in the 90-patient cohort. The TMA was
constructed with 1-mm-diameter cores using a manual tissue
arrayer (Beecher Instruments, Silver Spring, MD, USA) as
described previously [38].
2.3. Horizon PD-L1 Reference Standard Panel. The PD-L1
IHC Reference Standard consists of a genetically defined
11-spot custom cell line array (CLMA) with a range of
negative, low, medium, and strong protein expressing cell
lines developed using Horizon Discovery's gene editing
technology. Parental cells were purchased from a commercial
source and were characterised short tandem repeat (STR)
analysis. Cell lines were engineered under the control of
promoters of different strengths that resulted in a range
of controlled PD-L1 protein expressing cell lines by IHC.
Individual cell lines in the 11 spot CLMA were exten-
sively characterized and verified using molecular assays,
IHC, and quantitative digital pathology by Horizon Discov-
ery.
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2.4. Immunohistochemistry. All IHC was performed in an
integrated laboratory (Northern IrelandMolecular Pathology
Laboratory) that has UK Clinical Pathology Accreditation
[39]. Sections were cut from the whole face or TMA blocks
for H&E staining and IHC.The initial H&E section was used
to assess TMA quality and appropriate tumour, lymphoid,
or stromal content for subsequent IHC localizations and
analysis. Sections for IHC were cut at 4 microns on a rotary
microtome, dried at 37∘C overnight, and then used for IHC
that was performed on automated immunostainers (Ven-
tana BenchMark or Leica Bond-Max, Milton Keynes, UK).
See Supp Table 2 for primary antibody, pretreatment, and
biomarker detection details all of which were optimised prior
to application to TMA sections. Subsequently, all sections
were visualized with diaminobenzidine, counterstained with
haematoxylin, and then dehydrated and tape-mounted using
a Sakura autostainer. All slides were scanned on an Aperio
AT2 Digital scanner at x40.
2.5. Tumour Infiltrating Lymphocyte (TIL) Assessment. TILs
were assessed by three independent experienced immunohis-
tochemists onH&E sections as recommended by the Interna-
tional TILs working group 2014 [40]. TILs were reported as
percentage stromal TILs of thewhole face sections or Tumour
rich (T) cores of the TNBC TMA.
2.6. Image Analysis. Digital pathological analysis of the IHC
stained TMA slides was performed using QuPath [36, 41],
an open-source image analysis programme created in-house.
All x40 scanned slides were imported into the programme.
Dearraying of the TMA and tissue detection was carried out
to identify the areas of tissue available for cellular analysis.
Cores were removed following strict exclusion criteria; e.g.,
tissue cores that contained <100 tumour cells were removed
from analysis. Rigorous QC steps were taken to remove
necrosis, tissue folds, and entrapped normal structures; this
was confirmed by a second reviewer with frequent consulta-
tion. To minimise the risk of false positive detection, manual
removal of positive macrophage staining was conducted as
PD-L1 expression by macrophages is well recognised and
edited out where possible. Positive staining was defined as
the presence of any discernible DAB positivity localised
in the membrane and/or cytoplasm. Instances of punctate
granular DAB stainingwere considered positive and in highly
expressing cases a strong expression pattern of membrane
staining was seen on tumour epithelial cells.
Quantitation of PD-L1 was conducted as previously
described [36]. Briefly, intensity thresholds were set for cel-
lular DAB detection, under consultation with a pathologist.
Percentage positive data was extracted from each TMA core
and averaged across replicates.
2.7. RNA In Situ Hybridization for PD-L1. Manual chro-
mogenic RNAScope for PD-L1 (Hs-CD274 transcript vari-
ant 1: sequence region 124-1122 cat. No. 600861, Advanced
Cell Diagnostics, 3960 Point Eden Way Hayward, CA
94545, USA) was performed on TMA sections as previously
described [42]. RNAscope for positive control probe PPIB
(313910 Accession # NM 000942.4) and negative control
probe DapB (310043 Accession # EF191515) were also per-
formed on selected TMA sections. Image analysis on selected
regions of interest within the TMA cores of PD-L1-probewas
performed using Spotstudio Software from ACD with user-
defined thresholds after slides were scanned using an Aperio
scanner at x40 resolution.
2.8. Statistical Analysis. Lin’s concordance analysis was used
to examine the relationship between the PD-L1 scores using
different antibodies with two-sided correlation coefficients
reported. Results were interpreted using the cutoffs proposed
by McBride [43]. Fisher’s exact test was used to test correla-
tion between PD-L1 and lymph node status. Chi-squared test
was used to assess correlation between PD-L1 and CD4 or
CD8. Numbers were converted to percentages for graphing
purposes only. A Mann Whitney test was used to test the
association between PD-L1 and immune gene expression and
TIL scores. Kaplan Meier curves were used to investigate
the relationship between PD-L1 and patient survival using
the log-rank test or alternatively Cochran-Mantel-Haenszel
chi-squared test where indicated using Prism6. Multivariate
analysis and step-wise regression were carried out using
the R package MASS using the clinical parameters Age,
Tumour Stage (categorised as T1 and T2-4), and Lymph node
involvement. All Hazard ratios and p-values are presented in
Supp Tables 4-6. Statistical tests were two sided, and p-values
less than 0.05 were considered to be statistically significant.
3. Results
In order to assess the reliability of PD-L1 analysis using
the digital pathology platform, QuPath, we first utilised a
genetically defined 11-spot custom cell line array PD-L1 IHC
Reference Standard from Horizon Discovery (Figure 1(a)).
We compared three commercially available antibodies [22,
44–47] across different automated staining platforms. Anal-
ysis showed almost no PD-L1 staining in the null cell line
standards (A1-2) and similar high expression in the high
expressing cell line standards (C3-6). More varied expression
was observed in the low to medium expressing cell line stan-
dards (B1-4, C1-2). In general there was good concordance
between the different staining protocols with the exception of
the Abcam (28-8) antibody using the BenchMark automated
staining platform (Supp Table 3). When the technical repro-
ducibility of each antibody was compared based on platform
choice, excellent concordance was observed for SP142 with
similar levels of expression detected regardless of platform.
More disparate levels of expression that varied according
to platform choice were observed for the Cell Signalling
and Abcam antibodies (Figure 1(b)). SP142 was therefore
chosen for further IHC studies given the observed technical
reliability and its clinical relevance as a companion diagnostic
[48].
In addition to IHC, PD-L1 may also be quantified using
in situ hybridisation using RNAScope. In situ PD-L1 mRNA
expression was not detectable in the null cell line standards
(A1-2). As seen with the IHC experiment, more varied
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Figure 1: (a) Map of the Horizon Discovery PDL1 Reference Standard panel demonstrating negative, low, medium, and strong protein
expression (Data provided by Horizon Discovery). (b) Histogram of IHC-determined protein and RNAScope-determinedmRNA expression
of PDL1 in the Horizon Discovery custom cell line panel. IHC was performed with 3 different antibodies (Abcam (28-8), Spring Bioscience
(SP142), and Cell Signalling (405.9A11)) and on the Bondmax and Benchmark automated platforms. IHC was quantified using the QuPath
software. RNAScope was quantified using SpotStudio (ACD).
expression was observed for the low to medium expressing
cell line standards (B1-4, C1-2). Increased expression was seen
in the high cell line standards (C3-5) although there appears
to be discordance between protein expression (measured
by IHC) and mRNA (as measured by RNAScope) in 2 of
the 3 high cell lines (C4-5) (Figure 1(b)). This could reflect
posttranslational regulation of PD-L1 protein or the fact
that the protein based quantification does not account for
intensity of staining.
Based on these results, we took forward the SP142 IHC
on the Benchmark platform as well as the RNAScope assay
for assessment in patient samples.
In order to fully investigate the role of PD-L1 as a
biomarker we initially focussed our assessment on TNBC as
it demonstrates the greatest range of PD-L1 expression and
most significant correlation with patient outcome.Therefore,
we constructed a bespoke TMA that would allow us to
compare not only the different technology platforms (IHC,
Journal of Oncology 5
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Figure 2: (a) Areas of tumour cores targeted for use in subsequent tissue microarrays. Where sufficient material was available, three cores of
tissuewere taken from three areas, (1) enrichedwith tumour epithelium (green), (2) enrichedwith tumour stroma, (<50% tumour epithelium)
(black), and (3) enriched for lymphoid infiltrates within the tumour (red). (b) (i) Representative cores ranging from absent to high PD-L1
protein expression assessed by IHC using SP142, as indicated. Both raw immunohistochemistry images and QuPath cell detection masks are
shown. A magnified region is shown in an exploded view.The key displays the QuPath cell classifier on the mask images. (ii) Displays PD-L1
expression identified by RNAscope. Cores ranging from absent to high PD-L1 RNAScope expression, as indicated. A magnified region is
shown in an exploded view.
RNAScope) but also different tumour areas. For each patient a
total of nine cores were selected; three tumour rich cores (T),
three tumour cores with high stroma (TS), and three tumour
cores tumour from a lymphoid rich region (TL) (Figure 2(a)
and Supp Fig1A).
Microscopic IHC analysis with SP142 PD-L1 antibody
on individual TMA cores demonstrated various expression
patterns of PD-L1 in the different tissue compartments
(Figure 2(b)(i)). When present on tumour epithelial cells the
pattern was of striking membranous staining coupled with
a granular cytoplasmic staining. Within the lymphoid com-
partment, or in individual tumour infiltrating lymphoid cells,
punctate cytoplasmic staining was observed with occasional
cells showing a more intense perinuclear pattern. As to be
expected using in situ mRNA detection, RNAScope based
assessment of PD-L1 expression showed varying numbers of
dots per cells within both tumour epithelial and lymphoid cell
types (Figure 2(b)(ii)). All tissues were deemed adequate for
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Figure 3: Kaplan Meier Plots of relapse free survival stratified based on PD-L1 expression above or below 1% as determined by the (i) SP142
or (ii) by RNAScope.
RNAscope assay by expression of the positive control probe
PPIB. No expression of the negative control probe bacterial
DapB was observed in any of the tissue samples.
In order to compare the quantification of PD-L1 by the
different technologies and the associated correlation with
clinical outcome, initial automated analysis was based on
total (epithelial and lymphoid) PD-L1 expression across all
9 cores per patient. A threshold of 1% was used to stratify
IHC-based PD-L1 expression as high (>1%) or low (<1%) in
keeping with the clinically relevant thresholds reported in the
literature with 44% of cases called PD-L1 positive using the
SP142 antibody. Median expression was used to dichotomise
the mRNA expression. While similar trends were observed
with high PD-L1 expression associated with increased relapse
free survival (RFS), only assessment of PD-L1 expression by
IHC using the SP142 antibody was significant correlation
(HR0.536 (95%CI 0.316-0.94) p=0.0294) (Figure 3). Similar
results were also seen with overall survival (OS) though this
did not reach significance (Supp Fig1B).While the assessment
of 9 cores representing three different regions of the tumour
provides some insight into intratumoural heterogeneity, sev-
enteen whole face sections (representing low, intermediate,
and high PD-L1 expression) were also assessed by IHC (Supp
Fig1C). All cases that scored negative in the TMAs were
confirmed as PD-L1 negative in the whole-face sections. All
PD-L1 positive cases in the TMA settings were confirmed
as positive in the whole-face setting. While variation in
the percentage of tumour epithelial cells expressing PD-
L1 was observed, there was significant correlation between
whole face and TMA-derived PD-L1 expression (p=0.0019).
Based on these findings an IHC-based approach to quantify
PD-L1 using the SP142 antibody was applied in all further
experiments.
Next we wanted to compare the correlation with sur-
vival of PD-L1 expression in the different regions of the
tumour (TS, T and TL). Galon and colleagues were the
first to highlight the importance of the immune contexture
showing that type, density, and location of immune cells
within colon cancer predict clinical outcome [49, 50]. The
expression of PD-L1 varied significantly between the tumour
regions (p=0.032)with the greatest range of PD-L1 expression
observed in the T cores (range 0–65.05%) (Figure 4(a)).
This appears to be of clinical importance while high PD-L1
expression was associated with improved outcome in all core
types; only the tumour rich (T) cores showed significance
in terms of RFS (HR 0.445 (95%CI 0.271-0.917) p= 0.0255)
(Figure 4(b)) with the same trend observed for OS though
not quite reaching significance potentially due to the length
of follow-up data available (5yr)(Supp Fig2A).
Following on from this we wanted to further determine
the importance of the cell context of PD-L1 expression.
Therefore PD-L1 was categorised based on expression within
the stroma (lymphoid cells) vs the tumour nest (tumour
epithelial and lymphoid cells). Analysis was restricted to the
tumour rich (T) cores given the significant correlation with
clinical outcome. The range of expression was very similar
and there was a highly significant correlation between stro-
mal and tumour derived expression (R=0.9569, p= <0.0001)
(Figure 4(c)). Furthermore, only 5 patients with >1% stro-
mal expression had <1% tumour expression and conversely
only 6 patients displayed >1% tumour expression with <1%
stromal expression. Given this strong overlap, it was not
surprising that both high tumour and stromal derived PD-
L1 were significantly associated with improved RFS (Tumour
HR 0.455 (95%CI 0.274-0.909) p=0.0237, Stroma HR 0.421
(95%CI 0.26-0.872) p=0.0164) (Figure 4(d)) with similar
though nonsignificant trends for OS (Supp Fig2B).
We next wanted to investigate the correlation between
PD-L1 and the immunemicroenvironment. First, we assessed
Tumour Infiltrating Lymphocytes (TILs) using themethodol-
ogy recommended by the International TILs Working Group
2014 [5] to report percentage stromal TILs. Using the same
cases utilised to assess PD-L1 whole face expression, a highly
significant correlation between percentage TILs assessed in
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Figure 4: (a) Box and whisker plot showing the range min. to max. of PD-L1 expression (determined by SP142) in the three different tumour
core types: stroma rich (TS), tumour rich (T), and lymphoid rich (TL). (b) Kaplan Meier Plots of relapse free survival stratified based on
PD-L1 expression above or below 1% in the three different core types (i)TS, (ii)T, and (iii) TL. (c) (i) Box and whisker plot showing the range
of min. to max. and (ii) the correlation between tumour and stroma derived PD-L1 expression within the tumour rich (T) cores. (d) Kaplan
Meier Plots of relapse free survival stratified based on (i) tumour or (ii) stroma derived PD-L1 expression above or below 1%.
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Figure 5: (a) Scatter plot of percentage stoma TILs (median and interquartile range indicated) in cases determined to be low (<1%) or high
(>1%) for PD-L1 expression (whole core assessment) in the tumour rich cores. (b) Intratumoural (i) CD4 and (ii) CD8 expression in PD-L1
low (<1%) and high (>1%) samples. (c) Box and whisker plots of gene expression derived (i) M1/M2 signature scores and (ii) CD68/CD8 ratio
in PD-L1 low (<1%) and high (>1%) samples.
TMA cores and whole face sections was observed (p =
<0.0001, R2 = 0.7456). Furthermore, as previously reported in
the context of anthracycline based chemotherapy [5, 51], high
TIL expression was significantly correlated with improved
survival when analysed as a continuous variable per 10%
increase (RFS HR 0.8611 (95%CI 0.7855-0.944) p=0.00143,
OS HR 0.8723 (95%CI 0.7811-0.9741) p=0.0153) or when a
receiver operating characteristic (ROC) curve was used to
determine the best cut-off and patient dichotomised based
on low (<30%) or high (>30%) stromal TILs (SuppFig2C).
Of interest, this cut-off was shown to have clinical relevance
in assessing the prognostic and predictive value of TILs in
HER2+ breast cancer [52]. A weak but highly significant
correlation was observed between PD-L1 expression and
percentage TILs in T cores (p=0.0001, R2 = 0.151) and when
analysed in the context of low (<1%) and high (>1%) PD-
L1, the percentage of TILs observed was significantly higher
in the high PD-L1 cases (p = <0.0001) (Figure 5(a)). It is
important to note that a number of PD-L1 low cases expressed
high levels of TILs indicating distinct biology driving these
immune-related biomarkers.
In order to further characterise the composition of the
immune infiltrate in the context of PD-L1 expression, we
utilised IHC and gene expression analysis that had been pre-
viously carried out on a subset (67/109) of the TNBC cohort
[9]. High PD-L1 expression was significantly associated with
high intratumoural CD4 (p=0.0123) and CD8 (p=0.0004)
(Figure 5(b)). No correlation was observed for stromal CD4
or CD8 or FOXP3 (intratumoural or stromal). Furthermore,
high PD-L1 was also associated with a more “anti-tumour”
M1-like phenotype as evidenced by the significantly higher
gene expression signature score (p=<0.0001) [53] and a
significantly lower ratio of CD68/CD8 gene expression (p=
<0.0001) [54] (Figure 5(c)).
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Figure 6: (a) Kaplan Meier Plots of relapse free survival stratified based on PD-L1 expression above or below 1% in breast cancer as a whole.
(b) Box and whisker plot showing the range (min. to max.) of PD-L1 expression in the different subtypes of breast cancer. Kaplan Meier Plots
of relapse free survival stratified based on PD-L1 expression above or below 1% in (c) TNBC, (d) Luminal A, (e) Luminal B/HER2 negative,
(f) Luminal B/HER2 positive, (g) HER2 positive, and (h) ER negative breast cancer.
We then wanted to extend the analysis of PD-L1 expres-
sion into other breast subtypes and this was achieved using
an additional cohort accessed through the Northern Ireland
Biobank (NIB). This was made up of 300 breast cancer
patients, all of which were treated with FEC, creating a
relatively uniform clinical cohort [37]. Given the fact that,
during the routine annotation and construction of TMAs
within the NIB, epithelial rich regions are selected and
therefore are comparable with the tumour rich (T) cores
from the bespoke TNBC TMA, we felt that this TMA was
suitable for analysis. In addition, most TNBCcases within the
300 cohort (n=59/69) are represented on the bespoke TNBC
TMA allowing direct comparison. Based on our previous
results, we did not classify PD-L1 expression based on tumour
or stromal expression but instead determined expression of
the entire core. 29% of cases were determined to be PD-
L1 positive (>1%) and interestingly, this was shown to be
significantly associated with improved RFS when the cohort
was analysed as a whole (HR 0.547 (95%CI 0.35-0.994) p=
0.0477) (Figure 6(a)). We then decided to look at PD-L1
expression and its potential correlation with outcome within
the subgroups as defined by the St Gallen Classification
[55]. There was a highly significant variation (p<0.0001)
in expression across the different subtypes with the great-
est range (0-76.04%) of PD-L1 expression observed in the
TNBC cases which is consistent with previously published
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data (Figure 6(b)). Of interest, HER2 enriched samples also
displayed a broad range of expressions albeit not as great as
TNBC.
As expected, high PD-L1 expression was associated with
improved RFS and OS in TNBC patients (HR 0.355 (95%CI
0.148-0.84) p= 0.019 and HR 0.255 (95% CI 0.087-0.861)
p=0.0269, respectively) (Figure 6(c) and Supp Fig3B). How-
ever, analysis of the other breast cancer subgroups revealed
some novel findings. High PD-L1 expression was associated
with improved RFS in Luminal A patients through given
the low number of patients with high expression (<13%);
this failed to reach significance (Figure 6(d)). Furthermore,
this trend was not seen in overall survival (Supp Fig3C).
PD-L1 expression was not associated with clinical outcome
in the highly proliferative Luminal B samples regardless of
HER2 status (Figures 6(e) and 6(f) and Supp Fig3D&E).
Unexpectedly, high PD-L1 was associated with improved
survival in the HER2 enriched subgroup. While this was
not significant in terms of RFS (Figure 6(g)), it did reach
significance in OS with no deaths observed in patients
with high PD-L1 (HR 0.215 (95%CI 0.062-0.745) p=0.0153)
(Supp Fig3F). This leads us to investigate the prognostic
role of PD-L1 in ER negative disease as a whole with the
novel finding that high PD-L1 is significantly associated with
improved RFS andOS in this subset of breast cancer (HR0.36
(95%CI 0.195-0.761) p=0.0063 and 0.154 (95%CI 0.103-0.526)
p=0.0005, respectively) (Figure 6(h) and Supp Fig3G). This
remained significant at a multivariate level with a stepwise
regression model demonstrating that both PD-L1 expression
and lymphnode involvement are both significantly associated
with clinical outcome (Supp Table 6C&D). Further analysis
showed no correlation between these two variables.
This is an important finding for this poor outcome group
of patients which represents 20-30% of all breast cancer cases
and is associated with a disproportionately high number of
deaths especially in the first five years following diagnosis.
4. Discussion
The role of PD-L1 as a prognostic and predictive biomarker is
an area of great interest within oncology due to its association
with the novel immune checkpoint inhibitors. It is also
showing great promise in the treatment of a range of cancer
types. However, inconsistent results have been obtained in
the analysis of the PD-L1 biomarker. We propose that lack
of an objective, reproducible and accurate approach to PD-
L1 quantification and scoring may, at least in part, underlie
this. Therefore, the aim of this study was to perform a
comprehensive study of PD-L1 as a biomarker in breast
cancer using automated tumour recognition and quantitative
IHC image analysis together with objective scoring systems
on uniform patient tissue cohorts with extensive clinical
annotation. We show that the use of different antibodies
during IHC can have a significant impact on the detected
PD-L1 expression and its association with clinical outcome.
This was compared to mRNA expression as determined
by RNAScope. We show here that high PD-L1 expression,
as measured by IHC using the Ventana SP142 clone on
a Ventana automated platform and quantified using the
QuPath analysis platform, is significantly associated with
better clinical outcome in TNBC treated with current stan-
dard of care chemotherapy. This observation was confirmed
using a second TMA in which a large proportion of the
TNBC cases were replicated. When immune topography was
taken into account, tumour rich cores showed the greatest
predictive powerwith analysis of PD-L1 expression regardless
of cell type (epithelial or lymphoid) demonstrating the most
clinical relevance. Looking at breast cancer as a whole, there
was also an association between high PD-L1 expression and
improved clinical outcome. Moreover, we show for the first
time that PD-L1 expression significantly predicts clinical
outcome in all ER negative patients, includingHER2 enriched
disease.
This study highlights the potential risk of obtaining
varied results when investigating the role of PD-L1 as a
biomarker and may explain some of the inconsistencies
within the field. As previously mentioned, there is a range
of commercially available antibodies for PD-L1 IHC studies.
Mahoney et al. have shown that the region of PD-L1 against
which the antibody is raised can have a significant impact
on the staining patterns observed [47]. They conclude that
antibodies raised against the cytoplasmic domain of PD-
L1 can clearly identify the membrane of PD-L1 positive
tumour epithelial cells and allowmore accurate scoring. Both
the Cell Signalling and the Ventana SP142 antibodies are
raised against this region while the Abcam antibody is raised
against the extracellular domain. Our results suggest that
the combination of cytoplasmic domain specific antibodies
and their analysis with a validated automated platform, as
epitomised by our results with the SP142 antibody, is the
best vehicle for IHC detection of PD-L1 in breast FFPE
tissue.This is consistent with its development as a companion
assay to the Roche/Genentech anti-PD-L1 immunotherapy,
MPDL3280A, and observed clinical utility in clinical trial
samples [46, 48, 56].
Current standard scoring systems for PD-L1 as a compan-
ion diagnostic to immunotherapy find clinical significance
in percentages of expression above or below 1% [57]. We
also show that the use of a 1% threshold for calling positive
PD-L1 expression has clinical utility in predicting outcome
in breast cancer in the context of standard of care. This
emphasises the importance of accurate reproducible scoring
that can discriminate low PD-L1 expression but, at the same
time, opens an area of diagnostic value (expression above
or below 1%) in which it is notoriously difficult to reach
interobserver concordance. As shown using the custom cell
lines panel, most interantibody variability was observed at
the low levels of expression while concordance was seen at
extreme positive or negative levels indicating that multiple
factors will impact detection of PD-L1 at clinically relevant
levels, as encapsulated by the clinical challenges we face,
reporting in our experience of routine PD-L1 diagnostic
reflex testing [58]. Quantification by image analysis provides
the potential to obtain accurate reproducible results at low
expression levels. The ability to dynamically identify sensitiv-
ity thresholds within QuPath allows users to visually review
PD-L1 detection to ensure accurate and robust assessment at
these low expression levels.
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This sensitivity and specificity has allowed us to elucidate
a role for PD-L1 in predicting response in patients within
the ER negative HER2 enriched subgroup. To the best of
our knowledge, this is the first time the utility of PD-L1
as a biomarker has been demonstrated to predict improved
outcome in this subgroup. Along with TNBC, this is a
subgroup of unmet clinical need.While use of HER2 targeted
agents has had undeniable clinical benefit, response rates
are low with best responses rates (∼50%) observed in the
neo-adjuvant setting with a combination of targeted agents
[59, 60]. Furthermore, for those who do respond, resistance
is common, meaning overall survival is poor. PD-L1 may
serve to inform clinicians which patients are likely to require
additional treatment options to achieve better outcomes.
Of interest, high levels of TILs are associated with better
response to Trastuzumab in both the neo-adjuvant and adju-
vant setting potentially associated with antibody-dependent
cell-mediated cytotoxicity (ADCC) mechanism of action of
the drug [61]. Furthermore, the combination of Herceptin
and PD1/PD-L1 blockade has shown greater tumour regres-
sion in mouse models of HER2+ disease [62]. These obser-
vations have led to the PANACEA trial investigating the use
of PD1 inhibitors in advanced, Trastuzumab resistant HER2-
positive breast cancer (NCT02129556). Final safety data and
efficacy results presented at ASCO 2018 are positive showing
that the trial has met its primary endpoint [63]. Due to the
historic nature of the patient cohort used in the current study,
only 2 patients received Trastuzumab and so no correlation
can be made between PD-L1 and response to the targeted
agent in this study. However, these results indicate that PD-L1
may predict response to standard of care treatment and thus
provides clinical utility in this setting. Moreover, our data
adds to the evidence from the PANACEA trial suggesting that
immune evasion is amechanismof resistance toTrastuzumab
as well as standard of care chemotherapy and contributes to
disease progression in advanced HER2+ breast cancer.
Muenst et al. [22] previously published that high PD-
L1 expression was associated with poor prognosis in breast
cancer as a whole. Upon subset analysis, this observation was
significant within the Luminal B HER2-, Luminal B HER2+,
and HER2 enriched and basal-like subtypes. This is in stark
contrast to our findings as well as numerous other findings
centred on PD-L1 expression as a positive prognostic factor
in TNBC [21, 23, 24]. However, the validity of their results
has previously been challenged with particular emphasis on
the choice of antibody used in the study [64].
In addition to highlighting the novel role of PD-L1 in
predicting outcome in ER-negative breast cancer, this study
has also shown that high PD-L1 expression is associated with
improved outcome in breast cancer as a whole. This is in
contrast to the overall findings from two recentmeta-analyses
showing high PD-L1 expression associated with poor out-
come [65, 66]. However, two studies fromwithin these meta-
analyses did also report a significant association between
high PD-L1 expression and improved outcome. One study
utilised the Abcam antibody, dichotomised patients based
on the median from an Allred scoring system and observed
a significant association between high PD-L1 expression
and OS [67]. The second study examined PD-L1 mRNA
utilising the same RNAScope in situ hybridisation assay
applied in this study. Schlaper et al. found that PD-L1 expres-
sion (any expression above the noise threshold determined
by quantification of a negative control) was significantly
associated with RFS and the presence of TILs [21]. This
highlights again the importance for consistency in how PD-
L1 is quantified and thresholds for positivity are determined.
It is also important to consider the treatment received by
patient cohorts. All patients within the NIB Breast cohort
received adjuvant anthracycline based chemotherapy. While
all molecular subgroups of breast cancer are represented, the
cohort does not include lower risk patients who are treated
without systemic chemotherapy.Therefore, the positive prog-
nostic role of PD-L1 may only be apparent in the context of
chemotherapy.
The finding that PD-L1 expression, regardless of the
cell type (epithelial or lymphoid), is prognostic is keep-
ing with the guidelines for the companion assay for Ate-
zolizumab using SP142 [68]. Furthermore, the strong cor-
relation between epithelial and stromal PD-L1 expression
indicates that expression driven by an adaptive immune
resistance may be of most clinical relevance in predicting
outcome in breast cancer. This is supported further by the
significant association between PD-L1 expression and an
“anti-tumour” Th1/M1 polarised tumour microenvironment
whichwehave previously shown to be significantly associated
with improved survival in the context of SoC chemotherapy
in TNBC [9]. This PD-L1 expression is likely driven by the
presence of DNA repair defects [69] which also underpins
the favourable response to DNA-damaging chemotherapies
and indicates that the cohort of patients that gain clinical
benefit from the current standard of care chemotherapy are
likely to be the same patients that will respond to PD1/PD-
L1 blockade. While significant, the correlation between PD-
L1 and percentage of stromal TILs was observed to be
weak with high TILs observed in cases with low PD-L1
expression. This further emphasises the complexities of the
interaction between the tumour and the host immune system
and highlights the continuous need for alternate treatment
options to be identified to improve outcome in patients who
do not display adaptive immune resistance.
5. Conclusion
This study highlights the need for high quality information
at multiple levels (e.g., quantification, knowledge of immune
topography/contexture, and clinical annotation) in order
to accurately interpret the utility of a biomarker. We have
shown the impact of high-resolution image analysis on PD-
L1 interpretation fromantibody choice to IHC versusmRNA-
based quantification. This comprehensive comparison would
not have been possible without the objective, reproducible
and accurate PD-L1 quantification provided by our digital
pathology platform QuPath. We believe this study provides
vital information impacting on the clinical delivery and
interpretation of PD-L1 as a biomarker and provides clarity
to the role of PD-L1 in the prediction of response to standard
of care in breast cancer.
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Supplementary Figure 1. (A) Overview of tissue microarray
design from the cores chosen in Figure 2A with each column
representing an individual patient. Where the size of the
tumour was insufficient, cores targeting enriched epithelium
were prioritized as denoted with ∗. (B) Kaplan Meier Plots of
overall survival stratified based on PD-L1 expression above or
below 1% as determined by the (i) SP142 or (ii) by RNAScope.
(C) Images (x5) from whole face sections of TNBC stained
with PD-L1, adjacent to where tumour rich TMA cores were
taken. (i) - No expression, (ii) - Low level of expression
on tumour epithelium∗ but also on surrounding stromal
cells, (iii) - High expression on tumour epithelium. Inlays
x15 magnification. Supp Figure 2. (A) Kaplan Meier Plots of
overall survival stratified based on PD-L1 expression above
or below 1% in the three different core types (i)TS, (ii)T and
(iii) TL. (B) Kaplan Meier Plots of overall survival stratified
based on (i) tumour or (ii) stroma derived PD-L1 expression
above or below 1%. (C) Kaplan Meier plots of (i) relapse free
and (ii) overall survival stratified based on percentage stromal
TIL expression in T cores above or below 30%. Supp Figure
3. Kaplan Meier Plots of overall survival stratified based on
PD-L1 expression above or below 1% in (A) breast cancer as
a whole, (B) TNBC, (C) Luminal A, (D) Luminal B/HER2
negative, (E) Luminal B/HER2 positive, (F) HER2 positive
and (G) ER negative breast cancer. Supplementary Tables.
Supp Table 1: Clinical and Pathological Characteristics of (A)
90 patients included in bespoke triple negative TMA, and
(B) the Breast 300 cohort. Supp Table 2: Antibody conditions
for IHC. Supp Table3: Lin’s concordance coefficients and
95% Confidence intervals for correlation between PD-L1
expression using three different antibodies and two different
automated staining platforms. Supp Table 4-6. Full details of
Hazard ratios, 95% confidence intervals and p-values for all
survival analysis. (Supplementary Materials)
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